Fundz

Rheavita Closes Eur 2.5 Million Series A Financing Co-Led By Novalis Biotech Acceleration And Pmv

PRIVATEJun 02, 2021

Amount Raised

€2.5 Million

Round Type

Series A

GhentBiotechnologyBiopharma

Description

RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing. The round was co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). Concurrent with the financing, Kjell Mortier from Novalis Biotech Acceleration and Stefan De Waele of PMV will join RheaVita’s Board of Directors.

Who else raised in Biopharma and Biotechnology around the same time

Companies in the same sectors as Rhea Vita that raised within 45 days of this round, from Fundz verified event records.

  • Oncoinvent ASA raised an undisclosed amount on June 29, 2021.
  • Arbutus raised $81M on June 23, 2021.
  • Camp4 Therapeutics Corp raised $45M (Funding Round) on June 15, 2021.
  • Surface Ophthalmics, Inc. raised $5.8M on June 10, 2021.
  • Ajax Therapeutics, Inc. raised $37M on June 1, 2021.
  • Clene Nanomedicine raised $9.3M on May 26, 2021.

Who to call at Rhea Vita, and when

A new round usually means Rhea Vita is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Rhea Vita raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Rhea Vita, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Rhea Vita. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Rhea Vita

Location

Ghent, East Flanders, Belgium

About

RheaVita has developed a continuous, controlled freeze-drying technology that integrates all the traditional freeze-drying process steps into one continuous production line. By spinning the glass vials during the freezing process, a thin layer of product coats the inner lining of the vial. Following drying, the final solid freeze-dried product is obtained. Compared to the traditional freeze-drying process, RheaVita’s approach has several advantages, including very fast product and process development with limited experimental efforts, avoiding scale-up issues, reducing cycle times, lower production costs, less clean room space requirements, improving quality assurance and improved and uniform product quality and process uniformity. The design process was accompanied by the development of a digital twin, a ‘virtual reality’ version of the system to facilitate future process development and optimization, assist with maintenance and repair as well as training of operators. RheaVita was founded in 2018 as a spin-out of Ghent University. For more information, please visit www.rheavita.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Rhea Vita raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Rhea Vita's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Rhea Vita raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.